<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> (CsA) is used to prevent rejection in transplantation and to treat autoimmune and <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> such as <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>-promoting effect of CsA remains controversial </plain></SENT>
<SENT sid="2" pm="."><plain>We report the case of a 24-year-old man who developed <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> of precursor-T-cell origin after 75 months of treatment with CsA for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The surface antigen phenotype of his leukemic cells was CD2+, CD3+, CD5+, CD7+, CD4-, CD8-, CD10-, CD20-, CD34-, CD41-, and CD56- </plain></SENT>
<SENT sid="4" pm="."><plain>Southern blot analysis revealed a monoclonal rearrangement of T-cell receptor-Jgamma nongermline fragments in HindIII digestion </plain></SENT>
</text></document>